Rossari Biotech Limited (Rossari), a Specialty-Chemicals manufacturer providing intelligent and sustainable solutions for customers across industries, Q3 FY 21 revenue is up by 29.3% to reach Rs. 210 crore. 

EBITDA at Rs. 34 crore as against Rs. 30.1 crore, up by 13% and PAT stood at Rs. 21.6 crore as against Rs. 18.3 crore, higher by 18%.

Commenting on the performance for the quarter, in a joint statement, Edward Menezes, Promoter & Executive Chairman and Sunil Chari, Promoter & Managing Director said, “We have delivered a healthy performance during the quarter, registering a top-line growth of 29%. Our HPPC business continues to record robust performance driven by healthy offtake witnessed in hygiene products and anti-viral portfolio sales. The TSC business is also seeing gradual normalization in demand and we expect this momentum to strengthen in the quarters ahead."

"The first phase of our greenfield facility at Dahej is fully operational. Full operationalisation of the unit is also progressing as per plan and we remain on-track to commission the plant by March 2021," added Menezes and Chari.

The company has a strong upcoming pipeline of new products, with impetus on sustainability and environment friendliness. This should also help the company to sustainably ramp-up utilization levels at its fully commissioned Dahej unit over the next 3-4 years.

The greenfield facility will have a total installed capacity 132,500 MTPA enhancing the total capacity of the company by 2.1x to 252,500 MTPA.